Durata Looks Beyond FDA: Reimbursement Changes May Offer Opening for Long-Acting Anti-infective
This article was originally published in RPM Report
Executive Summary
Is the FDA regulatory climate getting better for anti-infective development? One clear “yes” emerges from the approach being taken by Durata Therapeutics in a series of recent investor presentations: Durata is focusing beyond FDA on the next challenge – finding the right commercial opening for long-acting anti-infectives.